Body mass, BMI, plasma lipids, lipoproteins, and glucose homeostasis at baseline, and following placebo and rosuvastatin periods Dmitri Sviridov et al. Atherosclerosis 2007

Parameters of reverse cholesterol transport following placebo and rosuvastatin periods Dmitri Sviridov et al. Atherosclerosis 2007

Significant associations between plasma lipoproteins and cholesterol efflux after placebo and rosuvastatin treatment Dmitri Sviridov et al. Atherosclerosis 2007

Ratios of the cholesterol efflux values between placebo versus active treatment periods values with whole plasma incubations values following precipitation of apoB lipoproteins Ratios of the cholesterol efflux values between placebo versus active treatment periods shown as the changes from an arbitrary unity value. Panel A shows values with whole plasma incubations and Panel B shows the values following precipitation of apoB lipoproteins. The mean values of the arbitrary units are 7.1% with whole plasma (Panel A) and 3.9% with apoB depleted plasmas (Panel B). The values describe cholesterol released from cells to 2% plasma during 2 h incubations. Dmitri Sviridov et al. Atherosclerosis 2007

Relationships between percent cholesterol efflux and plasma concentrations of LDL-C, HDL-C and LpA-I during placebo period Dmitri Sviridov et al. Atherosclerosis 2007